15.06.2018
DEINOVE: Successful capital increase of € 8.5 million
Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia and Japan. The...
Press releases
23.05.2018
General meeting of May 23: Shareholders approve the acquisition of MORPHOCHEM
The General Meeting approved the contribution in kind of the BIOVERTIS (parent company of MORPHOCHEM) shares and options and the issuance...
16.04.2018
DEINOVE and GREENTECH announce the launch of HEBELYS®, the first cosmetic active ingredient resulting from their collaboration
HEBELYS ® is a natural active ingredient produced by the fermentation of Sphingomonas , a bacterium belonging to the DEINOVE proprietary...
13.04.2018
DEINOVE takes on a whole new dimension with the acquisition of MORPHOCHEM’s clinical-stage antibiotic compound
MORPHOCHEM's MCB3837 antibiotic compound aims to treat severe gastrointestinal infections caused by Clostridium difficile , a priority...
10.04.2018
DEINOVE introduces Phyt-n-Resist®, the first pure phytoene for skincare
Deinove scientific platform has designed an exclusive Deinococcus fermentation process to deliver the first pure Phytoene for application...
28.09.2017
2017 half-year consolidated results: stability of net loss major progress on R&D programs in health, nutrition and cosmetics
Cash position: +€6.6m at June 30, 2017 compared to +€9.3m at December 31, 2016. Half-year net loss of DEINOVE Group (composed of DEINOVE...
16.05.2017
Shareholders’ meeting of May 16, 2017: Hervé BRAILLY joins the Board of Directors
Hervé Brailly, co-founder and executive of Innate Pharma SA [IPH], one of the world's leading immuno-oncology specialists and one of the...
30.03.2017
2016 annual results: Strategic focus on track – promising results in the fields of health, nutrition and cosmetics
Cash position of €9.3 million, and net loss down 1% to €6.3 million Strategic focus on high value-added applications in the healthcare,...
23.01.2017
DEINOVE strengthens its Board in line with its strategic focus
Four directors of international standing and experts in pharmaceutical industry and antibiotics join the Board of Directors: Bernard Fanget...
11.01.2017
DEINOVE announces its financial calendar for 2017
DEINOVE (Alternext Paris: ALDEI), a biotech company that discovers, develops and produces high-value compounds from rare bacteria, notably...